Ticker

Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research is expected to for one company in the week ahead, and four lock-up periods will be expiring.

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public offering of 11,111,111 shares of its common stock at a public offering price of $18.00 per share.

City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in ​its US initial public offering, as biotech ‌companies press ahead with listings despite market uncertainty.

City Therapeutics is advancing next-generation RNAi therapeutics, with its lead program CITY-FXI targeting thrombosis and showing promising early Phase 1 trial results. CTY boasts significant big pharma collaborations, a strong investor syndicate, and experienced leadership, positioning it as a high-quality biopharma IPO candidate. IPO proceeds will fund CITY-FXI clinical trials, advance additional pipeline assets,…